[Nanomedicines for the treatment of serious diseases and dual research].

Abstract

The use of nanotechnologies for the encapsulation of pharmacologically active molecules (nanomedicines) has enhanced the delivery of these molecules within the body after administration. By releasing the active ingredient at the level of pathological cells and tissues, these nanocarriers help reduce toxicity while improving therapeutic efficacy. They also protect fragile molecules from rapid metabolization and can promote their intracellular penetration. Nanomedicines have made significant advances in various therapeutic areas such as oncology, infectious diseases, and several neurological disorders. They have also contributed to groundbreaking discoveries, including the introduction of the first mRNA vaccine (against COVID-19), and have improved certain imaging and diagnostic techniques, too. Depending on the country and therapeutic indications, between 40 to 60 nanomedicines are currently on the market, with over a hundred in clinical trials. This review aims to describe and discuss the characteristics and functionalities of the different generations of nanocarriers, from their inception to the present day, discussing the prospects they offer for the production of therapeutic proteins, for facilitating gene editing (CRISPR/Cas9), and for enabling immune checkpoint blockade in oncology. The potential of extracellular vesicles and exosomes as drug carriers is also explored. These advances compel researchers to consider the dual risks, both conscious and unconscious, that they may pose.